The discovery of potent and long-acting oral factor Xa inhibitors with tetrahydroisoquinoline and benzazepine P4 motifs
The discovery and evaluation of potent and long-acting oral sulfonamidopyrrolidin-2-one factor Xa inhibitors with tetrahydroisoquinoline and benzazepine P4 motifs are described. Unexpected selectivity issues versus tissue plasminogen activator in the form
Watson, Nigel S.,Adams, Carl,Belton, David,Brown, David,Burns-Kurtis, Cynthia L.,Chaudry, Laiq,Chan, Chuen,Convery, Máire A.,Davies, David E.,Exall, Anne M.,Harling, John D.,Irvine, Stephanie,Irving, Wendy R.,Kleanthous, Savvas,McLay, Iain M.,Pateman, Anthony J.,Patikis, Angela N.,Roethke, Theresa J.,Senger, Stefan,Stelman, Gary J.,Toomey, John R.,West, Robert I.,Whittaker, Caroline,Zhou, Ping,Young, Robert J.
p. 1588 - 1592
(2011/05/05)
1-Benzazepine-3-Sulfonylamino-2-Pyrroridones as Factor Xa Inhibitors
The invention relates to chemical entities of formula (I): and/or pharmaceutically acceptable derivative(s) thereof. The invention also relates to processes for the preparation of compounds of formula (I), pharmaceutical compositions containing compounds
-
Page/Page column 23-24
(2009/01/20)
More Articles about upstream products of 939043-61-5
Get Best Price for939043-61-51,1-Dimethylethyl 6-fluoro-7-[(3S)-2-oxo-3-({[(phenylmethyl)oxy]carbonyl}amino)-1-pyrrolidinyl]-1,3,4,5-tetrahydro-2H-2-benzazepine-2-carboxylate